您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Erythromycin-13C-d3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Erythromycin-13C-d3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Erythromycin-13C-d3图片
包装:1mg
规格:98%
市场价:4370元
分子量:738

产品介绍
A neuropeptide with diverse biological activities
货号:ajcx22438
CAS:N/A
分子式:C36[13C]H64D3NO13
分子量:738
溶解度:DMF: 15 mg/ml,DMSO: 15 mg/ml,Ethanol: 30 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Erythromycin-13C-d3is intended for use as an internal standard for the quantification of erythromycin by GC- or LC-MS. Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.1It is active against a host of bacterial genera, includingStreptococcus, Staphylococcus, andHaemophilus(MIC90s = 0.015-2.0 mg/l).2Erythromycin (10-40 mg/kg) dose-dependently inhibits the growth ofS. aureusin a mouse model of thigh infection.3It also inhibits the cytochrome P450 (CYP450) isoform CYP3A4in vitrowith IC50values of 33 and 27.3 µM for α-hydroxytriazolam and 4-hydroxytriazolam formation, respectively, following administration of triazolam, which is known to be metabolized primarily by CYP3A4.4,5Formulations containing erythromycin have been used in the treatment of bacterial respiratory and skin infections, pertussis, and a variety of other bacterial infections.


1.Wilson, D.N.The A-Z of bacterial translation inhibitorsCrit. Rev. Biochem. Mol. Biol.44(6)393-433(2009) 2.Kanatani, M.S., and Guglielmo, B.J.The new macrolides. Azithromycin and clarithromycinWestern J. Med.160(1)31-37(1994) 3.Hoogeterp, J.J., Mattie, H., and van Furth, R.Activity of erythromycin and clindamycin in an experimental Staphylococcus aureus infection in normal and granulocytopenic mice. A comparative in vivo and in vitro studyScand. J. Infect. Dis.25(1)123-132(1993) 4.Westphal, J.F.Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: An update focused on clarithromycin, azithromycin and dirithromycinBr. J. Clin. Pharmacol.50(4)285-295(2000) 5.Greenblatt, D.J., von Moltke, L.L., Harmatz, J.S., et al.Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequencesClin. Pharmacol. Ther.64(3)278-285(1998)